0.280
0.02 (6.14%)
| Previous Close | 0.264 |
| Open | 0.250 |
| Volume | 2,214,575 |
| Avg. Volume (3M) | 5,087,404 |
| Market Cap | 8,508,818 |
| Price / Earnings (Forward) | 16.61 |
| Price / Sales | 0.060 |
| Price / Book | 34.84 |
| 52 Weeks Range | |
| Earnings Date | 18 Nov 2025 |
| Profit Margin | -4.30% |
| Operating Margin (TTM) | -49.28% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | -42.90% |
| Quarterly Earnings Growth (YOY) | -33.70% |
| Total Debt/Equity (MRQ) | 351.59% |
| Current Ratio (MRQ) | 3.46 |
| Operating Cash Flow (TTM) | 12.72 M |
| Levered Free Cash Flow (TTM) | 7.68 M |
| Return on Assets (TTM) | -4.11% |
| Return on Equity (TTM) | -27.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (US) | Mixed | Bullish |
| Medical Distribution (Global) | Mixed | Bullish | |
| Stock | Zynex, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Core |
| % Held by Insiders | 48.37% |
| % Held by Institutions | 22.92% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2025 | Announcement | Zynex Financial Restructuring Puts Company on Path to Long-Term Success |
| 17 Nov 2025 | Announcement | Zynex Reports Third Quarter 2025 Financial Results |
| 14 Nov 2025 | Announcement | Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee |
| 14 Nov 2025 | Announcement | Zynex Sets Third Quarter 2025 Earnings Call |
| 14 Oct 2025 | Announcement | Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |